Pharyx, Inc. — Department of Health and Human Services SBIR Phase I: NCI

Description

The manufacture of personalized medicine products such as autologous cell based cancer immunotherapies is a tremendous challenge When the manufactured batch size is for a single patent new manufacturing systems are needed to reduce the cost and improve the quality of these individualized products The long term objectives of this project are to develop a microbioreactor based manufacturing platform to enable the low cost manufacture of autologous cell therapies at scales exceeding individual therapies per year Initial feasibility will be assessed by cultivating T cells in existing microbioreactors and optimizing process conditions for maximum cell density In addition process development to improve the efficiency of genetically modifying the target cells will be performed in order to improve product quality and process robustness Finally a microbioreactor system specifically for autologous cell therapy manufacturing with quality control sample preparation will be designed